New ointment approved for diaper dermatitis
Parents of infants suffering with fungal-infected diaper rash will now have a new form of treatment available. Vusion ointment containing 0.25% miconazole nitrate, 15% zinc oxide, and 81.35% white petrolatum has been approved by the FDA and is the first product for diaper dermatitis complicated by candidiasis.
New ointment approved for diaper dermatitis
Parents of infants suffering with fungal-infected diaper rash will now have a new form of treatment available. Vusion ointment containing 0.25% miconazole nitrate, 15% zinc oxide, and 81.35% white petrolatum has been approved by the FDA and is the first product for diaper dermatitis complicated by candidiasis. Vusion is indicated for use in infants as young as four weeks and should be applied at each diaper change. According to the manufacturer Barrier Therapeutics, some symptomatic relief should be seen within 72 hours, but treatment should continue for the entire seven days. Typically, Candida infections are characterized by a rash of bright red patches with irregular, raised borders and white scales on the surface. Full prescribing information is available at http://www.vusionointment.com/
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
